CURRICULUM VITAE
Name :
Dr. Mahmoud Mohamed Ghorab
Nationality:
Egyptian
Date of birth:
07-18-1941
Marital status:
married, two kids.
Qualification:
* Bachelor of Pharmaceutical Sciences (1961), Cairo
University.
* Master of Pharmaceutical Sciences in Pharmaceutics
(1966), Cairo university.
* PhD of Pharmaceutical Sciences in Pharmaceutics
(1969), Cairo University.
Past experience: *Pharmacist in the ministry of public health (1961).
* Demonstrator in the department of Pharmaceutics,
Faculty of Pharmacy, Cairo university, from (1962).
* Lecturer in the department of Pharmaceutics, Faculty of
Pharmacy, Cairo university, from (1969).
* Assistant professor in the department of Pharmaceutics,
Faculty of Pharmacy, Cairo university, from (1974).
* Visiting professor in the school of pharmacy London
university, England, from (1977) to (1978).
1
* Professor in the department of Pharmaceutics, Faculty
of Pharmacy, Cairo university, from (1980).
* Visiting professor in the department of Pharmaceutics,
Faculty of Pharmacy, Khartoum university, Sudan in
1981.
* Treasurer of the Egyptian pharmaceutical society,
(1987).
* Vice-president of the Egyptian pharmaceutical society,
(1988).
* Visiting professor in the college of Pharmacy, Rode
Island university, U.S.A. for 9 months in 1989.
* Head of the department of Pharmaceutics and
Pharmaceutical Technology, from July (1998) till July
(2001).
* Chairman of board of director of the Egyptian Research
and Development Company.
Scientific activity: Supervised a lot of Thesis for Master and PhD degrees,
in the science of Pharmaceutics and Pharmaceutical
Technology, 10 Masters and 7 PhDs.
List of publication: See attached.
List of patents: See attached.
Professional activity: Head of Giza pharmacy Syndicate for two
consecutive periods since (1988) till now.
* Advisor of the culture committee in the faculty of
pharmacy, Cairo university, from (1966).
2
* General supervisor of international students in the
ministry of high education from (1968-1969)
* Joined military service from (1969) to (1973).
* Participated and lectured in many scientific and
professional pharmaceutical conferences, which were
held locally and universally.
* Received American fulbright scholarship in 1987.
* Under secretary of promotion committee for professors
in the field of Pharmaceutics and Pharmaceutical
Technology from (1989), supreme council of university.
* Member of the board of directors (Global Napi drug
company) from (1995) till now.
* Consultant of the board of directors (CID drug
company) from (1996) till now.
*Consultant of the board of directors (MISR drug
company) from (1983) till now.
* Scientific consultant of (Memphis drug company) from
(1997) till now.
* Scientific consultant on the construction of the
antiseptic department at the Nile pharmaceutical
company (2005)
* Consultant of the Egyptian armed forces drug factory
(1996) till now.
3
* Member of the ministry of health committee for
auditing and licensing pharmaceutical manufacturing
facilities (2006-2009).
* Member of supreme drug committee in the Egyptian
health insurance organization.
* Chairman of the scientific committee for promoting
professors and associate professors (September 2008 –
current)
* Councilor in the police medical academy.
* Lecturing different courses for undergraduate students
in the field of pharmaceutics and pharmaceutical
technology.
* Teaching different courses for graduate students in the
field of industrial, hospital, clinical pharmacy and
cosmetics.
* Lecturing different courses for GMP validation, inprocess quality control, quality management, quality
assurance and total quality assurance for industrial
graduates.
* Teaching a course on facility planning, design and
construction of pharmaceutical firms.
* Member of the selection committee for professors
applying to the American fulbright scholarship, from
(1991) till now.
* Member of the supreme court of Ethics from (1995).
* Scientific consultant of pharmatica annual conference
4
and exhibition.
* Head of board of directors and the executive member
of ERDC (2001).
* Have three patents applied and commercially marketed
in the field of drug industry (Pystinon Tabs - Phyntoin
Caps. - Duropin Vials).
* Consultant for Rhon Polanc Rore company from 1996
to 2000).
Languages: English (very good), French (fair)
Address: Work: Faculty of Pharmacy, Cairo university, EI-Kasr EI-Eini
street, 11562, Cairo, Egypt.
Residence: Building 11, Abu EI-Maati street, apt. # 104, EI-Balloon, EIAgoza, Giza, Egypt.
Telephone No.: 00202/3467141, 3473341 and 0124436479.
5
List of publications and Conference presentations
[1] Hussein, A. M., Kassem, A. A., Tawfik, A. S. and Ghorab, M.,
"Pharmaceutical Studies of Some Iron Salts of Saccharic Acid"; J. Pharm.
Sci. U. A. R., Vol. 3, pp. 105-110 (1969).
[2] Hussein, A., M., Kassem, A., A., Amer, M. and Ghorab, M., "Evaluation
of Vitamin B12 in Pharmaceutical Hemopoeitic Preparations"; J. Pharm. Sci.
U. A. R., Vol. 3, pp. 311-324 (1969.)
[3] Kassem, A. A., Ghorab, M. and Abd EI-Maksoud, F., "Preparation of
Water Repellent Non Adhesive Surgical Dressings"; Bulletin of Faculty of
Pharmacy, Cairo Univ. Vol. XI, No.1, pp. 247-258 (1972).
[4] Ghorab. M., Mahrous, H., Geneidi, A. S. and Kassem, A. A., "Sodium
Chloride: Design and Study of an Oral and Controlled Release Tablets";
Bulletin of Faculty of Pharmacy, Cairo Univ. Vol. XI, No.1, pp. 259-269
(1972).
[5] Kassem, A. A., Said, S. A., Ghorab, M. and Abd EI-Maksoud, F., "The
Use of Silicones in Timica Lip Sticks"; Bulletin of Faculty of Pharmacy,
Cairo Univ. Vol. XI, No.2, pp. 163-174 (1972).
[6] Kassem, A. A., Ghorab, M. and Assem, A., "Film Coating of B.
Complex Vitamins Tablets"; Bulletin of Faculty of Pharmacy, Cairo Univ.
Vol. XI, No.2, pp. 155-162 (1972).
[7] Kassem, A. A. and Ghorab, M., "Controlled Release of Potassium Ions in
Dihydrochlorothiazide potassium Chloride Saliuretic Tablets"; Bulletin of
Faculty of Pharmacy, Cairo Univ. Vol. III, No.1, pp. 53-60 (1973).
[8] Kassem, A. A., Ghorab, M. Said, A. A. and Abd EI-Maksoud, F., "Use
of Semithicone in Antacid Digestive Medications"; Proc. VIII Conf. Pharm.
Sci. Cairo, Egypt, pp. 163-166 (Feb 1974).
[9] Geneidi, A. S., Mahrous, H., Ghorab, M. and Kassem, A. A., "Detection
of Aggregates formation in Some Antibiotics Ion Exchange Resin Systems";
6
Proc. VIII Conf. Pharm. Sci. Cairo, Egypt, pp. 167-170 (Feb 1974).
[10] Kassem, A. A. and Ghorab, M., "Formulation and Preparation of Some
Effervescent Granules"; Bulletin of Faculty of Pharmacy, Cairo Univ. Vol.
XIV, No.1, pp. 139-145 (1975).
[11] Kassem, A. A., Ghorab, M., EL-Gendy, A. R. and Abd EI-Maksoud, F.,
" The use of Siliconized Lubricants for the Tablet Manufacture"; Bulletin of
Faculty of Pharmacy, Cairo Univ. Vol. XIV, No.2, pp. 231-237 (1975).
[12] EI-Shater, S., Ghorab, M., Zaki, S. and Kassem, A. A., " Formulation
and Stability Studies of Piperazine Citrate Solution"; Bulletin of Faculty 'of
Pharmacy, Cairo Univ. Vol. XIV, No.2, pp. 215-229 (1975).
[13] EI-Samaligy, M., Ghorab, M. and Kassem, A., "Antacid Efficiency of
Magnesium Trisilicate in Presence of Various Polymeric Materials";
Bulletin of Faculty of Pharmacy, Cairo Univ. Vol. XIV, No.1, pp. 147-154
(1975).
[14] Ghorab, M., EI-Samaligy, M. and Kassem, A., "Influence of
Siliconization on the Flowability of Certain Mineral Silicates and Drugs";
Bulletin of Faculty of Pharmacy, Cairo Univ. Vol. XIV, No.2, pp. 177-186
(1975).
[15] Abd EI Rehim, A. and Ghorab, M., "Use of Acrylic Resins for the
Preparation of Depot Antispasmodic-sedatic Microperle Granulates"; 5th
Congo of Arab. Pharma. Union 8-11, No.1, p. 215 (1976).
[16] Ghorab, M., "Kinetic Degradation of Methenamine in Urine and
Buffered Solutions"; Ibid, Union 12-15, No.1, p. 221 (1976).
[17] Ghorab, M., "Formulation and Biopharmaceutical Study on Caffeine
and Caffeine Sustained Release Preparations"; Ibid, Union 16-19, No.1, p.
227 (1976).
[18] Ghorab, M., "Formulation and Biopharmaceutical Evaluation of
Methenamine and Drugs Containing Methenamine"; Ibid. Union 20-23,
No.1, p. 233 (1976).
7
[19] Beckett, A. H. and Ghorab, M., "Evaluation of Different Products of
Ammonium Chloride to Control Urinary pH in Humans"; Bulletin of Faculty
of Pharmacy, Cairo Univ. Vol. XV, No.1, pp. 120-125 (1976).
[20] Ghorab, M. "Urine Acidifiers, Evaluation and Biopharmaceutical
Study"; Ibid. Vol. XV, No.1, pp. 126-130 (1976).
[21] Kassem, A. A., Zaki, S., Ghorab, M., EI-Samaligy, M. and Saleh, S. L.,
"Degradation Kinetics of Tartar Emetic Solution"; Bulletin of Faculty of
Pharmacy, Cairo Univ. Vol. XVI, No.1, pp. 19-26 (1977).
[22] Kassem, A. A., Zaki, S., Ghorab, M., EI-Samaligy, M. and Saleh, S. L.,
"Stability and Formulation of Tartar Emetic Injectable Solutions"; Bulletin
of Faculty of Pharmacy, Cairo Univ. Vol. XVI, No.1, pp. 27-35 (1977).
[23] Kassem, A. A., Ghorab, M. and Assem, M. A., " Formulation and
Stability of Lipotropic Tablets"; Ibid, Vol. XVIII, No.1, pp. 75-83 (1978).
[24] EI-Samaligy, M., Ghorab, M. and Abd Elbary, A., "Formulation and
Biopharmaceutical Evaluation of Timed Release Aspirin"; XVI Egyptian
Conf. of Pharm. Sci., Cairo (1980).
[25] Abd Elbary, A., EI-Samaligy, M. and Ghorab, M., "Bioavailability of
Tetracyclin From Different Commercial Brands"; XVI Egyptian Conf. of
Pharm. Sci., Cairo (1980).
[26] Ghorab, M. and EI-Samaligy, M., "Evaluation of Nitrofurantoin in
Different Pharmaceutical Dosage Forms"; XVI Egyptian Conf. of Pharm.
Sci., Cairo (1980).
[27] Ghorab, M., Mansour, F. F. and Afifi, N. N., "Dissolution Profile of
Indomethacin from its Various Solid Dispersions"; J. Egypt. Pharm. Sci.,
Vol. 28, No 1-4, pp. 339-344 (1987).
[28] Ghorab, M., Mansour, F. F. and Afifi, N. N., "Release Characteristics of
Indomethacin from its Pellets Coated with Various Release Retardants"; J.
Egypt. Pharm. Sci., Vol. 28, No 1-4, pp. 345-352 (1987).
8
[29] Ghorab, M, Mansour, F. F. and Afifi, N. N., "Bioavailability of
Indomethacin from Different Controlled Release Capsule Formulations"; J.
Egypt. Pharm. Sci., Vol. 28, No 1-4, pp. 353-360 (1987).
[30] Ghorab, M. M., Kassem, A. A. and Abdel Ganal, N. A.,"Diazepam
Injectable Solutions: Formulation and Stability Studies"; Bull. Fac. Pharm.
Cairo Univ., No.1, pp. 48-80 (1989)
[31] Ghorab, M., EI-Mahrouki, G. M. and Makky, A. A., "Interactions of
Certain Non-steroidal Anti-inflammatory Drugs with Aromatic Amino
Acids. 1. Complexation of Indomethacin with Aromatic Amino Acids";
Bulletin of Faculty' of Pharmacy, Cairo Univ., Vol. 28, No.3, pp. 27-30
(1990).
[32] Ghorab, M. M., EI-Mahrouki, G. M. and Makky, A. A., " Interaction of
Certain Non-steroidal Anti-inflammatory Drugs with Aromatic Amino
Acids. Interactions with Mefenamic Acid with Aromatic Amino Acid";
Ibid., pp. 31-34
(1990).
[33] Ghorab, M. M., EI-Mahrouki, G. M. and Makky, A. A., "In-vitro and
In-Vivo Evaluation of Certain Indomethacin-Aromatic Amino Acid
Complexes"; Ibid, pp. 35-39 (1990).
[34] Ghorab, M. M., Zei, H. and Luzzi, L. A., "Preparation of Controlled
Release Anti-cancer Agents Flourouracil-ethyl cellulose Microspheres"; J.
Microencapsulation, Vol. 7, No.4, pp. 447-454 (1990).
[35] Ghorab, M. M., Mahmoud, H. A. and Afifi, M. M., "In-vitro and InVivo Evaluation of Cinnarzine Solid Dispersion"; XXII Conference of
Pharmaceutical Sciences of the Egyptian Pharmaceutical Society 17-19
(Dec. 1991 ).
[36] Ghorab, M. M., Mahmoud, H. A. and Afifi, M. M., "Preparation and
Biopharmaceutical Evaluation of Kellin Coprecipitates"; Ibid.
[37] Farag, S. I., EI-Shater, S. and Ghorab, M. M., "Flurbiprofen-load
9
Ethocil Microspheres. Preparation and Evaluation"; Ibid.
[38] Farag, S. I., EI-Shater, S. and Ghorab, M. M., "Preparation and
Evaluation of Flurbiprofen Solid Dispersion in Various Release Retardants";
Ibid.
[39] Nour, S. A., Abd EI- Hady, S. E. and Ghorab M. M., "A Natural
Coloring Agent from Hipiscus Subdarifa, Effect of pH and Vehicle
Changes"; Ibid.
[40] Ghorab, M., Hamza, Y. and EI-Assasi, A., "Influence of Certain
Eudragits on Sustainment of Ibuprofen Tablets"; Pharmacy World Congress,
Washington, D.C., U.S.A., 40-spt-007, Sept. (1991).
[41] Ghorab, M., Hamza, Y. and EI-Assasi, A., "Effect of Polystyrene on
Sustainment of Dexropropoxphene HCI Tablets"; FIP, 92 Congress, Lyon,
France (Sept. 1992).
[42] Ghorab, M., Hamza, Y. and EI-Assasi, A., "Sustainment of Release of
Dextropropoxyphene HCI with Polystyrene Via Microencapsulation
Technique"; Ninth International Symposium on Microencapsulation, Lyon,
France (Sept. 1992).
[43] Ghorab, M., Ammar, H., EI.,Ridy, M. S. and Ghorab, M. M.,"
Evalution of the Anti-schistosomal Effect of Praziquentel in a liposomal
Delivery Systems in Mice", Intern. J. Pharm. 103, 237 (1994).
[44] Ghorab, M, Tayel, S. and Hussein, S., "Formulation and Evaluation of
Rifamycin SV Sodium Eye Drops", 24th Egyptian Conference of
Pharmaceutical Sciences, Cairo, Egypt, Dec. (1994).
[45] Ghorab, M, Tayel, S. and Hussein, S., "Formulation and Evaluation of
Rifamycin SV Sodium Dermatological Perparations", 24th Egyptian
Conference of Pharmaceutical Sciences, Cairo, Egypt, Dec. (1994).
[46] Ghorab, M, Tayel, S., Hussein, S. and Ahmady, A., "Microbiological
Studies of Certain Rifamycin SV Sodium Formulae Prepared For External
10
Use", 24th Egyptian Conference of Pharmaceutical Sciences, Cairo, Egypt,
Dec. (1994).
[47] Ammar, H. O., Ghorab, M., EI-Nahas, S. A. and Ghorab, MM.,
"Improvement of Some Pharmaceutical properties of Drugs, Part 4.
Chloropromazine Hydrochoride; Pharmazie, 50(12) H, 805-808 (1995).
[48] Ammar, H. 0., Ghorab, M., EI-Nahas, S. A. and Ghorab, MM.,
"Improvement of Some Pharmaceutical properties of Drugs by Cyclodextrin
Complexation, Part 5. Theophylline; Pharmazie, 51(1), 42-46 (1996).
[49] Ammar, H. O., Ghorab, M., EI-Nahas, S. A. and Ghorab, MM.,
"Improvement of Some Pharmaceutical properties of Drugs by Cyclodextrin
Complexation, 6. Ampicillin; Pharmazie, 51 (8), 568-570 (1996).
[50] Ammar, H. O., Ghorab, M., EI-Nahas, S. A., Omr, S. M.and Ghorab, M
M., "Interaction of Dicumarol with (3-Cyclodextrin"; Egypt. J- Pharm- Sci.,
Vol. 37(1-6),431-444 (1996).
[51] Ammar, H. O., Ghorab, M., EI-Nahas, S. A., Omr, S. M.and Ghorab, M
M., "Interaction of Hydrochlorothiazide with (3-Cyclodextrin"; Egypt. J.
Pharm. Sci., Vol. 37(1-6), 445-458 (1996).
[52] Badawy, S., Ghorab, M. M. and Adeyeye, C. M., "Bioavailability of
Danazol-Hydroxypropyl--Cyclodextrin Complex by Different Routes of
Adminstration"; Int. J. Pharm., 145, 137-143 (1996).
[53] Badawy, S., Marshall, M., Ghorab, M.M. and Adeyeye, C.M.,
"Evaluation of Sulfobutylether Derivatives of Cyclodextrins as Solubility
and Dissolution Enhancers of Danazol", Drug Develop. Ind. Pharm., August
(1996).
[54] Ammar, H. O., Ghorab, M., EI-Nahas, S. A. and Makram, T. S.,
"Interaction of Oral Anticoagulant with Methyl Xanthines; Pharmazie,
52(12), 946-950 (1997).
[55] Ammar, H. 0., Ghorab, M., EI-Nahas, S. A. and Makram, T. S.,
11
"Improvement of the Biological Performance of Oral Anticoagulant Drugs,
Part 2, Dicumarol"; Pharmazie, 52(9), 727 (1997).
[56] Ammar, H. 0., Ghorab, M., EI-Nahas, S. A. and Makram, T. S.,
"Improvement of the Biological Performance of Oral Anticoagulant Drugs,
Part 1. Warfarin"; Pharmazie, 52(8), 627-631 (1997).
[57] Ghorab, M. M., Afifi, N. N. and Makky, A. M., "Formulation and
Pharmaceutical Evaluation of Sulindac Suspensions"; XXV Conf. of Egypt.
Pharm Sci., (Dec. 1998).
[58] Ghorab, M. M., Afifi, N. N., Makky, A. M. and Abd EI-latif, "Further
Evaluation of Certain Sulindac Suspensions"; XXV Conf. of Egypt. Pharm
Sci., (Dec. 1998).
[59] Ammar, H. O., Ghorab, M., EI-Nahas, S. A., Emara, L. H. and
Makram, T. S., "Inclusion Complexation of Furosemide in Cyclodextrins,
Part 1, Effect of Cyclodextrins on the Physicochemical Characteristics of
Furosemide"; Pharmazie., 54(2), 142-144(1999).
[60] Ammar, H. 0., Ghorab, M., EI-Nahas, S. A., Emara, L. H. and Makram,
T. S., "Inclusion Complexation of Furosemide in Cyclodextrins, Part 2,
Implication on Bioavailability"; Pharmazie. 54(3), 207-10(1999).
[61] Ammar, H.A., el-Nahhas, S.A., Emara, L.H., Ghorab, M.M., Salama,
H.A., Discrepancy among dissolution rates of commercial tables as a
function of the dissolution method. Part 7: Aspirin. Pharmazie. 52(2), 145-9
(1997).
[62] Ghorab, M., Nada, A.H., Ghorab, M.M., Hammady, T.H., Comparative
study of some additives for the improvement of terfenadine performance.
Pharmazie. 57(11), 772-3 (2002).
[63] Ammar, H.O., Salama, H.A., Ghorab, M., El-Nahhas, S.A., Elmotasem,
H., Design and evaluation of prednisolone acetate eye drops with prolonged
effect. Egy. J. Pharm. Sci. 46, 9-20 (2005).
12
[64] Ammar, H.O., Salama, H.A., Ghorab, M., Mahmoud, A.A.,
Formulation and biological evaluation of glimepiride-cyclodextrin-polymer
systems. Int J Pharm. 309(1-2), 129-38 (2006).
[65] Ammar, H.O., Salama, H.A., Ghorab, M., Mahmoud, A.A., Implication
of inclusion complexation of glimepiride in cyclodextrin-polymer systems
on its dissolution, stability and therapeutic efficacy. Int J Pharm. 320(1-2),
53-7 (2006).
[66] Ammar, H.O., Salama, H.A., Ghorab, M., El-Nahhas, S.A., Elmotasem,
H., A transdermal delivery system for glipizide. Curr Drug Deliv. 3(3), 33341 (2006).
[67] Ammar, H.O., Ghorab, M., El-Nahhas, S.A., Kamel, R., Design of a
transdermal delivery system for aspirin as an antithrombotic drug. Int J
Pharm. 327(1-2), 81-8 (2006).
[68] Badr-ElDin, S.M., Elkheshen, S.A., Ghorab, M.M., Inclusion
complexes of tadalafil with natural and chemically modified -cyclodextrin:
Tablet formulation, in-vitro and in-vivo evaluation. Eur. J. Pharm.
Biopharm., 70(3), 819-827 (2008)
[69] EL-Ashmoony, M.M., Elkheshen, S.A., Ghorab, M.M., Enhancement
of solubility and dissolution of simvastatin via complexation with
cyclodextrins and co-precipitation with phospholipids. XXXI Conference of
Pharmaceutical Sciences, Egypt (25 – 28 Dec. 2008).
[70] Ghorab, M.M., Tag, R., Salah, S., in-vitro and in-vivo evaluation of
poly D-L-lactide nanoparticles viscous dispersions for the ocular delivery of
ofloxacin. XXXI Conference of Pharmaceutical Sciences, Egypt (25 – 28
Dec. 2008).
[71] Ghorab, M.M., Tag, R., Salah, S., Preparation and characterization of
ofloxacin loaded biodegradable polyD-L-lactide nanoparticles. A factorial
design study. XXXI Conference of Pharmaceutical Sciences, Egypt (25 – 28
Dec. 2008).
[72] El-Ashmoony, M.M., Elkheshen, S.A., Ghorab, M.M., Formulation and
in-vitro evaluation of directly compressed tablets containing simvastatin
inclusion complexes with cyclodextrin and co-precipitation with
13
phospholipids. XXXI Conference of Pharmaceutical Sciences, Egypt (25 –
28 Dec. 2008).
[73] Ghorab, M., Ammar, H.O., El-Nahas, S.A., Kamel, R., Polymeric
matrix system for prolonged delivery of tramadol hydrochloride, Part 1:
Physicochemical evaluation. AAPS PharmSciTech. 10(1), 7-20 (2009).
[74] Ammar, H.O., Ghorab, M., El-Nahhas, S.A., Kamel, R. Polymeric
matrix system for prolonged delivery of tramadol hydrochloride, part II:
biological evaluation. AAPS PharmSciTech. 10, 1065-70 (2009).
[75] Ammar, H.O., Salama, H.A., Ghorab, M., Mahmoud, A.A.,
Nanoemulsion as a potential ophthalmic delivery system for dorzolamide
hydrochloride. AAPS PharmSciTech. 10, 808-19 (2009).
[76] H. O. Ammar, M. Ghorab, S. A. El-Nahas, I. M. Higazy, Proniosomes
as a Carrier System for Transdermal Delivery of Tenoxicam, Intern. J.
Pharm., (2010)
[77] Walaa Ahmed El-Dakrouri, Howaida Kamal Ibrahim, Mohamed
Khaled Ghorab and Mahmoud Mohamed Ghorab, Enhancement of the
Intranasal Delivery of Insulin via A Novel Mucoadhesive Carbapol Gel., J.
Pharm. Pharmacology, (62):1-8 (2010).
[78] H. O. Ammar,H. A. Salama, M. Ghorab, A. A. Mahmoud,
Development of Dorzolamide Hydrochloride in situ Gel Nanoemulsion for
Ocular Delivery., Drug Dev. and Ind. Pharm., 36(11):1330-1339 (2010).
[79] Howaida K. Ibrahim, Ahmed M. Attia and Mahmoud M. Ghorab,
Biopharmaceutical Evaluation of formulated Metformin/Rosiglitazone
Tablets., Drug discoveries and Therapeutics, 4 (2): 100-108 (2010).
[80] H. O. Ammar, M. Ghorab, A. A. Mahmoud, T. S. Makram, S. H.
Noushi, Preparation and of hydrogels as a vehicle for topical delivery of
Lonoxicam, Int. j. drug formulation research. 2 (5), 254-73 (2011).
[81] H. O. Ammar, M. Ghorab, A. A. Mahmoud, T. S. Makram, S. H.
Noushi, Topical liquid crystalline gel containing Lonoxicam/ cyclodextrin
complex, J. Ind. Phenom. Macrocycle chem., accepted in press.
14
The research activities during my academic studies were concerned with two
main topics, they are the topics on the agenda of researches which include:
1- Controlled release medications:
To justify several arguments, minimizing the frequency of adminstration,
overcoming patient incompliance, reducing side effects of drugs.
This is clear in the articles No.4, 7, 15, 24, 27, 29, 33, 34, 35, 40, 41 and 42.
2- Drug complexation:
In order to:
A- Improve drug performance through the modification of drug stability,
dissolution and bioabsorption.
B- Increasing the stability of drugs against different destructive factors,
prolonging its shelflife.
C- To mask unpleasent taste and bad odour.
Check articles No.48, 49, 50, 51, 52, 53, 54, and 59.
15
List of Bioequivalence studies
Capsules:
 Bioequivalence study of Macrofuran Capsules 50 mg for AI Kahira
pharmaceutical Company. (Urinary antiseptic)
 Bioequivalence study of Rheumacid Capsules 25 mg for AI Kahira
pharmaceutical Company. (N.S.A.I.D)
 Bioequivalence study of Omepral Capsules 20 mg for Memphis
Company. (Peptic ulcer)
 Bioequivalence study of Ofloxacin Capsules for Memphis Company.
(Antibiotic)
Tablets:
 Bioequivalence study of Septazole Tablets for Alexandria Company
for pharmaceuticals. (Chemotherapeutic agent).
 Bioequivalence study of Diabyl Tablets 80 mg for Memphis
Company. (Anti- Diabetic).
 Bioequivalence study of Glibenase Tablets for Arab Company.
(Antidiabetic).
 Bioequivalence study of Salex Tablets 40 mg for Arab Company.
(Diuretic).
 Bioequivalence study of Tensilol Tablets 100 mg for Memphis
Company. (Antihypertensive ).
 Bioequivalence study of Tensilol Tablets 100 mg for Memphis
Company. (Antihypertensive ).
 Bioequivalence study of Atenolol Tablets 100 mg for sedico
Company. (Antihypertensive ).
 Bioequivalence study of Pyrazinamide Tablets for Memphis
Company. (Antilyprozy).
 Bioequivalence study of Pynox Tablets for Alex Company.
(Antiplatlets).
 Bioequivalence study of Sedopram Tablets 20 mg for sedico
Company. (Antidepressent).
16
Dry suspension:
 Bioequivalence study of Ampicillin Syrup 250 mg for Misr
Pharmaceutical Company. (Antibiotic)
 Bioequivalence study of Cephadrol Syrup 250 mg for Arab Company.
(Antibiotic).
17
Training Programs
 Application of HPLC in GC of drug.
 Current Good Manufacturing Practice.
 Validation.
 Stability of drug.
 Quality assurance.
 Development, design and Supervision of the construction of the
Antiseptic Department in Nile Company (2004).
18
Patents:
1- M. M. Ghorab, S. A. Nour ;"A New Method For the Formulation of
Pyridostigmine bromide" Application no. 2002080902.
2- M. M. Ghorab; "Development of Benzathine Pencillin suspension's
syringability" Application no. 2003060613.
3- M. M. Ghorab, D. M. Ghorab, H. K. Ibrahim; " Formulation and
Evaluation of Complexes of Phenytoin Sodium with betacyclodextrin"
Application no. 2003070625.
4- M. M. Ghorab ;"Formulation and Evaluation of Sodium Rifocin S.V. in
the form of a topical antimicrobial cream". Application no. 2003060615.
5- M. M. Ghorab; "Formulation and Evaluation of Sodium Rifocin S.V. in
the form of an Ophthalmic solution". Application no. 2003060614.
6- M. M. Ghorab, Y. S. EI Saharty, S. M. Badr; "Formulation of Sildenavil
Citrate in the form of easily desintegrable tablets" Application no.
2004010039.
7- M. M. Ghorab, M. M. EI Ashmony ; "Formulation of Solconazole Nitrate
in the form of gelatinous microemulsions" Application no. 2005040194.
8- M. M. Ghorab; "A stable and safe Chloramphinicol Ophthalmic solution"
Application no. 2005040214.
9- M.M. Ghorab; “Formulation of tadalafil in tablet form containing
inclusion complexes with HP--CD Application no. 20081010036.
19
Technology Transfer
Three of the registered patents have been applied in the field of drug
industry, on a large-scale production, producing products of high quality and
fulfilling the specifications stated in the approved patents.
These tedious processes of technology transfer acquired special treatments
and modifications to be economically worthy, Costs less and verify more
profits of time, energy, money and labour.
These patents are:
1- Benzathine Pencillin Pat. No. 2003060613 (Durapen S vials. El Nile
Company) used in the treatment Rheumatic heart fever.
2- Pyridostigmine Bromide Pat. No. 2002080902 (Pystinon tablets, Alex.
Co.) of Mythenia Gravis.
3- Phyntoin Sodium Pat. No. 2003070625 (Phyntoin Caps. Memphis CP.)
used in the treatment of Epilipsy.
The above stated products are currently, used for a long period of time.
20